Story Feb. 6 - X4 Pharmaceuticals: The rare disease biotech is laying off 43 employees—equivalent to 30% of the company’s total staffers—along with the discontinuation of its “research ...

"Without careful consideration of the impact of these changes, we risk long-term damage" to medical research, writes Dr. George Weiner.

The stock value and growth potential of a biotech firm depend on the type of diseases it treats. This might also include the research that the firm does as it supports other companies, diseases or ...

DaVita Inc. announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating ...